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MicrovesiclesFibroblasts are the most abundant cells in connective tissue and, with ﬁbrillar extracellular matrix, form the
structural scaffolding of organs. In solid tumors, interaction with cancer cells induces ﬁbroblasts
transdifferentiation into an activated form, which become a fundamental part of the tumor stroma. Within
tumor microenvironment stromal and cancer cells engage a crosstalk that is mediated by soluble factors, cell–
cell contacts and extracellular vesicles trafﬁcking.
Here we report that ﬁbroblasts have the ability to transfer a remarkable amount of proteins and lipids to
neighboring cells, in an ectosome-dependent fashion, identifying a novel and native property of these cells.
Cancer-associated ﬁbroblasts show an enhanced production and delivering of ectosomes to cancer cells
compared to normal ﬁbroblasts. As a consequence of this phenomenon, tumor cells increase their proliferation
rate, indicating that ectosome-mediated trafﬁcking could be a relevant mechanism mediating the trophic
function of activated connective tissue on tumor cells.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The extracellularﬂuids of tissues contain inorganic ions,metabolites,
polysaccharides, proteins and also a remarkable quantity of hetero-
geneous, membrane-delimited vesicles, comprehensively deﬁned
extracellular vesicles (EVs)1. EVs are secreted by many cell types,
including hematopoietic-derived cells [1,2], intestinal epithelial cells
[3], tumor cells [4] and neuronal cells [5], and are classiﬁed, depending
on their origin, as exosomes, ectosomes or apoptotic bodies [6].
Exosomes are intraluminal vesicles with a diameter of 30–100 nm [7],
which are formed inside the late endosomes and released upon fusion
with the plasma membrane. On the other hand, ectosomes are directly
produced by plasmamembrane blebbing, and are larger than exosomes,
ranging from 100 nm to 1 μm in diameter [8]. All EVs contain both ge-
netic material (mRNA, miRNA and DNA molecules) and proteins, andr associated ﬁbroblasts; CFDA-
s, human prostatic ﬁbroblasts;
; SOD2, superoxide dismutase
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degli Studi di Firenze, Vialeonce uploaded, may modify the phenotype of recipient cells [9–11].
Hence, EVs trafﬁcking between neighboring cells is currently consid-
ered as an additional form of intercellular communication besides para-
crine crosstalk and signaling mediated by cell–cell contact.
Recent evidence indicates that EVs have a major role in cancer, and
particularly in tumormicroenvironment,where they have been proposed
tomodulate [12] stromal cell biology, angiogenesis, and immune evasion.
Tumor microenvironment is comprised of transformed cells and non-
transformed stromal cells, including cancer-associated ﬁbroblasts
(CAFs), endothelial cells, lymphocytes, macrophages and bone marrow-
derived stem/progenitor cells [13]. A functional and metabolic crosstalk
between cancer cells and their stromal counterpart is critical for tumor
progression [14]. CAFs represent the main component of tumor stroma
and are involved in many aspects of tumor biology. In fact, CAFs have
been reported to: i) boost tumor cell proliferation [15] and motility [16,
17]; ii) induce epithelial to mesenchymal transition (EMT) of prostate
and breast cancer cells, favoring metastatic spreading [18,19]; iii) co-
migrate with cancer cells in the bloodstream favoring cell implantation
in distant tissues [20,21]; and iv) induce a metabolic reprogramming in
cancer cells which results in increased proliferation rate [22,23].
In the context of tumor microenvironment the vast majority of
studies have focused on exosomes produced by cancer cells [8] and on
their effects on tumor progression, inﬂuencing the local and systemic
environment [24]. Very recently, Luga et al. [25] showed that CD81-
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motility and metastatic potential of breast cancer cells, providing evi-
dence for a bidirectional ﬂux of information between CAFs and tumor
cells. Here we show that in a coculture model recapitulating tumor mi-
croenvironment, transfer of proteins and lipids is mainly directed from
CAFs to cancer cells, and is mediated by ectosome trafﬁcking. The trans-
fer of a speciﬁc subset of proteins, that include glycolytic enzymes, pro-
teins implied in redox regulation and structural proteins contributes to
sustain cancer cells proliferation rate.
2. Materials and methods
2.1. Cell cultures
Human prostate cancer (PC3 and DU145) and humanmelanoma
(A375) cell lines were purchased from European Collection of Cell
Culture (ECACC). Human dermal ﬁbroblasts (HDFs) were from
Invitrogen™ Life Technologies and NIH-3T3 mouse ﬁbroblasts
were from Istituto Zooproﬁlattico Sperimentale della Lombardia e
dell'Emilia-Romagna. Prostate ﬁbroblasts were obtained from
healthy prostatic tissue (HPFs) or from prostate cancer specimens
(CAFs) from patients undergoing radical prostatectomy. Written
informed consent was obtained by all patients in accordance with
the Ethics Committee of Azienda Ospedaliera Universitaria Careggi
(Firenze, Italy).
Experiments were performed on tissue obtained from several pa-
tients (all with Gleason 4 + 5, pT3aN0). Tissue was digested overnight
in 1 mg/mL collagenase I. Cell suspension was centrifuged at 1500 ×g
for 5 min. The resulting ﬁbroblast-rich pellet was suspended and plated
in DMEM containing 10% fetal bovine serum (FBS, Euroclone). Purity of
the preparation was checked measuring expression of the epithelial
markers, E-cadherin and cytokeratins. Identity of HPFs and CAFs was
conﬁrmed by morphology and by staining for Fibroblast Activation
Protein and α-Smooth Muscle Actin.
Cells were cultured in DMEM supplemented with 2 mM glutamine,
with penicillin (100 U/mL) and streptomycin (100 μg/mL), and with
10% fetal bovine serum (FBS, Euroclone), and incubated at 37 °C in a
humidiﬁed atmosphere of 5% CO2.
2.2. Materials
Unless otherwise speciﬁed all reagents were purchased from Sigma/
Aldrich. Carboxyﬂuorescein diacetate succinimidyl ester (CFDA-SE) was
from Invitrogen™ Life Technologies. Polyvinylidene diﬂuoride (PVDF)
membrane and Immobilon Western Chemiluminescent HRP Substrate
were from Millipore. Coculture separation was performed by MACS®
MicroBeads andMACS® Column (Miltenyi Biotec). 14C-amino acids mix-
ture, 14C-lactic acid and the storage phosphor screen were from Perkin
Elmer. 2D Quant kit, Ettan™ IPGphor™ system, IPGphor Cup Loading
Strip Holders and the ECL plus immunodetection systemwere purchased
from GE Healthcare, USA. ReadyStrip™ IPG strips were purchased from
Bio-Rad. Anti-enolase (sc-7455), anti-integrin β1 (sc-8978), anti-GM130
(sc-16268) and anti-MMP2 (sc-10736) antibodies were purchased
from Santa Cruz Biotechnology. Anti-glyceraldheyde-3-phosphate de-
hydrogenase (GAPDH) (ab9385) and anti-superoxide dismutase 2
(SOD2) (ab13533) antibodies were from Abcam, anti-β-tubulin
(T8328) was from Sigma/Aldrich, anti-pyruvate kinase M1 (PKM1)
(15821-1-AP) was from Proteintech, anti-pyruvate kinase M2 (PKM2)
(4053S) was from Cell Signaling Technology, anti-vimentin was from
Thermo (RV203), anti-CD81 (555675) antibody was from BD
Biosciences.
2.3. Transwell coculture system
Fibroblasts and tumor cells were cocultured by using transwell per-
meable supports (Transwell® Corning-Costar) with pore size of 8.0 μmor of 0.4 μm. DU145 were plated in the lower compartment, ﬁbroblasts
were plated on the upper side insert in a 1:2 ratio. The transwell system
was used for proliferation assay and for ﬂuorescence analysis of protein
transfer.
2.4. Proliferation assay
Cell proliferation was evaluated using CFDA-SE. DU145 cells were
labeled with the dye at the concentration of 2.5 μM and then plated
alone or with ﬁbroblasts. At the end of the experiment, cells were de-
tached, ﬁxed in 3% paraformaldehyde and analyzed by ﬂow cytometry.
The ﬂuorescence values were analyzed by ModFit software to estimate
the proliferation index.
2.5. Fluorescence analysis of protein transfer
Transfer of proteins from donor to recipient cells was evaluated
using CFDA-SE. Donor cells were labeled with the dye at the concentra-
tion of 10 μM and then plated with recipient cells both in coculture and
in Transwell systems. For ﬂow cytometry cellswere detached after 24 or
40 h, and ﬁxed in 3% paraformaldehyde. The ability of donor cells to
transfer proteins was evaluated measuring the ratio between the
ﬂuorescence of recipient cells after coculture with donor cells and
their autoﬂuorescence.
For confocal microscopy, cells in coculture were grown on glass
coverslips. Immediately after plating and after 6 h cells were washed
with PBS and ﬁxed in 3% paraformaldehyde for 20 min at 4 °C. After
additional washes with PBS, cells were mounted with glycerol
plastine and observed by confocal ﬂuorescence microscopy (Leica
TCS SP5).
2.6. Analysis of lipid transfer
Transfer of lipids fromdonor to recipient cells was evaluated by ﬂow
cytometry or by confocalmicroscopy essentially as described for protein
transfer, but after staining with CellVue®.
2.7. Conditioned media preparation
Tumor cellswere grown in starvationmedium for 48h, after that the
medium was recovered, centrifuged at 1000 ×g for 20 min to discard
cell debris and used to culture ﬁbroblasts for 24 h. Soon after the activa-
tion, ﬁbroblasts were used for the experiments.
2.8. Cocultures separation
DU145were labeledwith CFDA-SE and then plated in coculturewith
ﬁbroblasts. After that the cells were detached, separated according to
the manufacturer's protocol of MACS® Column Technology and the
two cell populations recovered were counted with Bürker chamber.
Different aliquots of each cell sample were used to determine the sepa-
ration efﬁciency by ﬂow cytometry, to measure the radioactivity (CPM,
counts perminute) by liquid scintillation counter (Perkin Elmer), and to
perform 2D electrophoresis (2DE) separation. The percentage purity of
donor and recipient cells after the coculture separation was higher
than 98%. The CPM values measured for recipient cells were calculated
subtracting the radioactive contamination due to donor cells, and vice
versa.
2.9. Puriﬁcation of membrane vesicles secreted by CAFs
The culture supernatant recovered from radioactively labeled
CAFs was centrifuged at 1000 ×g for 20 min to discard cell debris.
The supernatant was then centrifuged at 10,000 ×g for 40 min. The
pellet was resuspended in PBS and centrifuged again at 10,000 ×g
for 40 min obtaining the ectosomes fraction. The supernatant was
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suspended in PBS and centrifuged again at 100,000 ×g for 90 min
obtaining the exosomes fraction. Serumpresent inﬁbroblasts growthme-
dium was previously deprived of exosomes by centrifugation at
100,000 ×g for 90 min.
For proliferation experiments, ectosomes and exosomes were
puriﬁed from CAFs culture medium and added to DU145 cell culture
for 40 h.
For electrophoresis and Western blot analysis both the ectosomes
and the exosomes were suspended in 100 μL of 2-fold concentrated
Laemmli electrophoresis buffer (without β-mercaptoethanol and
bromophenol blue) and assayed for protein content by the BCA
method. 40 μg aliquots from each sample were additioned with
β-mercaptoethanol and separated by SDS-PAGE. Subsequently gels
were electroblotted onto PVDF membranes for detection or stained
with colloidal blue Coomassie. The blots were incubated with anti-
enolase, anti-β-tubulin, anti-GAPDH, anti-PKM1, anti-PKM2, anti-
vimentin, anti-SOD2, anti-CD81, anti-GM130, anti-integrin β 1 and
anti-MMP2. After incubation with secondary antibodies, the blotting
was developed by using the ECL plus immunodetection system and
visualized by autoradiography.Fig. 1. Confocal microscopy analysis of cell to cell protein and lipid transfer. Fibroblasts were la
DU145 tumor cells in 2:1 ratio on glass coverslips; in their turns, DU145 tumor cells were labe
ﬁbroblasts in 2:1 ratio on glass coverslips. Immediately after plating and after 6 h the cells wer2.10. Dynamic light scattering analysis
Membrane vesicles secreted by ﬁbroblasts were puriﬁed as
described above, and resuspended in 800 μL of sterile PBS, after that
their size distributions were obtained using Zetasizer Nano S Dynamic
Light Scattering device and analyzed by the DTS software (Malvern
Instrument Ltd). The analysis was performed at 25 °C.
2.11. 14C-lactic acid into proteins
Tumor cells were cultured for 24 hwith or without CAFs, both in co-
culture or in Transwell systems, and 14C-lactic acidwas added to culture
medium for additional 24 h. Cells were then detached and resuspended
in 20% trichloroacetic acid, placed on ice for 30 min and centrifuged at
13,500 ×g for 25 min. The amount of 14C-proteins within the resus-
pended pellet was determined by scintillation counting.
2.12. 14C-amino acids incorporation
Fibroblasts were cultured for 72 h in exosomes-deprived complete
medium supplemented with a mixture of 14C-amino acids. Cells werebeled (A) with CFDA-SE or (B) with CellVue® and then plated in coculture with unlabeled
led (C) with CFDA-SE or (D) with CellVue® and then plated in coculture with unlabeled
e ﬁxed in paraformaldehyde and observed by confocal ﬂuorescence microscopy.
Fig. 1 (continued).
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1000 ×g for 10 min, and plated in coculture with tumor cells.
2.13. Time course of 14C-protein transfer from CAFs to prostatic tumor cells
The percentage of CAFs protein mass transferred to tumor cells was
evaluated as the ratio between CAFs radioactivity and tumor cells
(DU145 and PC3) radioactivity measured for single cell after coculture
and separation (see above). Data sets (“6 h” vs “16 h” and “16 h” vs
“24 h”) were compared and statistical signiﬁcance was obtained.
2.14. Sample preparation and 2D electrophoresis
For 2DE, DU145 and CAFs were co-cultured for 6 h of coculture, and
then harvested by centrifugation at room temperature and separated by
MACS® Column Technology. Eight independent experiments were
performed. Cells were washed twice in PBS and resuspended in
50mM Tris–HCl pH 7.0, 1% NP-40, 150 mMNaCl, 2 mM ethylene glycol
bis(2-aminoethyl ether)tetraacetic acid, 100 mM NaF] containing
protease inhibitor cocktail. After a brief sonication, protein extracts
were clariﬁedby centrifugation at 14,000×g for 10min andprecipitatedwith chloroform/methanol. Thepelletwas resuspended in 8Murea, 4%3-
((3-cholamidopropyl)dimethylammonio) propanesulfonic acid (CHAPS),
and 20 mM dithiothreitol (DTT). Protein content was determined using
the 2D Quant kit (GE Healthcare Life Sciences). For each sample, four
2DE replicate gels were made, in order to assess biological and analytical
variation. The ﬁrst dimension was carried out on ReadyStrip™ IPG strips,
pH 3–10 NL (Bio-Rad) using the Ettan™ IPGphor™ system. IPG-strips
were rehydratedwith 350 μL of lysis buffer and 2% v/v carrier ampholyte,
for 12 h at room temperature. Eight hundred μg samples per strip, were
loaded by cup loading in the IPGphor Cup Loading Strip Holders, with
the sample cup system at the anodic side of IPG strips. IEF was performed
at 20 °C according to the following voltage steps: 30 V for 30 min, 200 V
for 2 h, 500 V for 2 h, from 500 to 3500 V in 30 min, 3500 V for 5 h,
from 3500 to 5000 V in 30 min, 5000 V for 4 h, from 5000 to 8000 V in
30 min, 8000 V until a total of 60,000 V/h was reached. After focusing,
IPG strips were equilibrated in equilibration buffer (6 M urea, 75 mM
Tris–HCl pH 8.8, 29.3% glycerol, 2% SDS) containing 1% (w/v) DTT for
15 min and then in the same equilibration buffer containing 2.5%
iodoacetamide for a further 15 min.
The second dimension was carried out on 9–16% polyacrylamide
linear gradient gels (18 cm × 20 cm × 1.5 mm) at 40 mA/gel constant
Fig. 2. Flow cytometry analysis of cell to cell protein and lipid transfer. (A) Fibroblasts of prostatic or dermal originwere labeledwith CFDA-SE and then plated in coculture in 2:1 ratiowith
unlabeled prostatic cancer cells (both DU145 and PC3) and A375, respectively; in their turns, cancer cells of prostatic origin (both DU145 and PC3) and A375 were labeled with CFDA-SE
and then plated in coculture in 2:1 ratiowith unlabeled ﬁbroblasts of prostatic and dermal origin, respectively. (B) HPFs, HDFs andNIH-3T3were labeledwith CFDA-SE and then plated in
coculture in a 2:1 ratio with their unlabeled counterpart. (C) Fibroblasts of prostatic origin were labeled with CellVue® and then plated in coculture in 2:1 ratio with unlabeled DU145; in
their turns, DU145were labeled with CellVue® and then plated in coculture in 2:1 ratio with unlabeled ﬁbroblasts of prostatic origin. After 24 h cells were detached and analyzed by ﬂow
cytometry. The data represent the fold increase of recipient cells ﬂuorescence intensity, respect to their autoﬂuorescence intensity, calculated on an average of ﬁve independent
experiments (**p b 0.05; ****p b 0.005; ******p b 0.0001).
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blue staining. The stained gels were scanned with an Epson Expression
1680 Pro image scanner. Gels were dried on a Slab Gel Dryer (Hoefer,Fig. 3. Quantitative analysis of protein transfer mediated by non activated ﬁbroblasts and CAFs.
PC3 conditionedmedium (CAFs), were labeledwith CFDA-SE and then plated in coculturewith
dermal origin (HDFs) and ﬁbroblasts activated with A375 conditioned medium (CAFs), were l
2:1 ratio in starvation medium. After 24 h cells were detached and analyzed by ﬂow cytometr
their autoﬂuorescence intensity, calculated on an average of four independent experiments (**model CD 2000) and autoradiographed for the appropriate time
(2 days for ﬁbroblasts 2DE gel and 15 days for DU145 2DE gel). Images
were acquired on a Cyclone Storage Phosphor Scanner (Perkin Elmer).(A) Primary ﬁbroblasts of prostatic origin (HPFs) and ﬁbroblasts activated with DU145 or
unlabeled healthy ﬁbroblasts in a 2:1 ratio in starvationmedium. (B) Primary ﬁbroblasts of
abeled with CFDA-SE and then plated in coculture with unlabeled healthy ﬁbroblasts in a
y. The data represent the fold increase of recipient cells ﬂuorescence intensity, respect to
p b 0.05; ***p b 0.01; *****p b 0.001). CM: tumor cells conditioned media.
Table 1
Time course of protein transfer from CAFs to prostatic tumor cells.
6 h 16 h 24 h
% CAFs protein mass transferred to
DU145
[0.5 ± 0.2]** [1.9 ± 0.4]** [4.0 ± 0.4]**
% CAFs protein mass transferred to
PC3
[0.9 ± 0.3]*** [2.7 ± 0.4]*** [9.5 ± 0.9]***
The percentage of CAFs protein mass transferred to tumor cells was obtained from the
ratio between CAFs “single cell radioactivity” and DU145 or PC3 “single cell radioactivity”
after coculture and separation. ***p b 0.01. **p b 0.05.
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Twenty-four protein spots, corresponding to radiolabeled proteins
transferred from CAFs to DU145 tumor cells, were manually excised.
Tryptic digests of each protein spot were obtained according to a previ-
ously published method (Shevchenko et al., 1996), with modiﬁcations.
Brieﬂy, samples were washed in 50 mM 1:1 NH4HCO3/CH3CN,
reduced in 10 mM DTT for 30 min at 56 °C, carbamidomethylated
with 55 mM iodoacetamide for 30 min in the dark, and incubated for
1 h at 37 °C in with 20 μL of a 20 μg/mL trypsin solution (Trypsin Prote-
omics Sequencing Grade, Sigma) in 40 mM NH4HCO3 with 10% CH3CN.
An additional 30 μL of 40mMNH4HCO3 with 10% CH3CNwere added to
each sample and incubated overnight at 37 °C. The reactionwas stopped
adding triﬂuoroacetic acid at a ﬁnal concentration of 0.1%. The superna-
tant was collected and the gel was further extracted with 0.1%
triﬂuoracetic acid in 50% CH3CN. The extracts were combined and
then analyzed on a MALDI-TOF/TOF mass spectrometer (Ultraﬂex III,
Bruker Daltonics, Bremen, Germany) using Flex Control 3.0 as data
acquisition software. A 0.75 μL volume of the sample was mixed
with 0.75 μL of the matrix (saturated solution of α-cyano-4-
hydroxycinnamic acid in 50% (v/v) CH3CN and 0.5% (v/v) TFA) on the
anchorchip target plate and allowed to dry. Spectra were acquired in
reﬂectron mode over the m/z range 860–4000 for a total of 500 shots.
The instrumental parameters were chosen by setting ion source 1 at
25 kV, ion source 2 at 21.5 kV, pulsed ion extraction at 20 ns and detec-
tor gain at 7.7×. The instrument was externally calibrated prior toFig. 4.Dependence of overall protein transfer and tumor cells proliferation bydonor/recipient ce
DU145 and (B) with PC3 both in 2:1 ratio and 1:2 ratio. After 40 h cells were detached and anal
intensity, respect to their autoﬂuorescence intensity, calculated on an average of three independ
and then plated alone or in coculture with CAFs. After 40 h cells were detached and analyzed b
lated on an average of three independent experiments (***p b 0.01).analysis using the Bruker Peptide Calibration standard kit. All the
resulting mass lists were cleaned from contaminant masses, such as
those from matrix, autodigestion of trypsin and keratins. Mass ﬁnger-
printing searching was carried out in Swiss-Prot databases using MASCOT
(Matrix Science Ltd., London, U.K., http://www.matrixscience.com) soft-
ware. The taxonomy was restricted to Homo sapiens, allowing a
mass tolerance of 50 ppm, and setting the number of accepted
missed cleavage sites to one. Alkylation of cysteine by carbamido-
methylation was assumed as ﬁxed modiﬁcation. The experimental
mass values were monoisotopic. No restrictions on protein molec-
ular weight and pI were applied. The criteria used to accept identi-
ﬁcations included the extent of sequence coverage, number of
matched peptides and probabilistic score sorted by the software.lls ratio. Fibroblasts of prostatic originwere labeledwith CFDA-SE and then plated (A)with
yzed by ﬂow cytometry. The data represent the fold increase of recipient cells ﬂuorescence
ent experiments (*p b 0.1; **p b 0.05). (C) DU145 and (D) PC3were labeledwith CFDA-SE
y ﬂow cytometry. The data show the fold increase of tumor cells proliferation index calcu-
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Each peptide mixture was submitted to capillary-LC-μESI-MS/MS
analysis on anUltimate 3000HPLC (Dionex, San DonatoMilanese,Mila-
no, Italy) coupled to a LTQ Orbitrap mass spectrometer (Thermo Fisher,
Bremen, Germany). Peptides were concentrated on a PepMap100 C18
precolumn cartridge (300 μm i.d. × 5 mm, 5 μm, 100 Å, LC Packings
Dionex) and then eluted on a homemade capillary column packed with
Aeris Peptide XB-C18 phase (180 μm i.d. × 15 cm, 3.6 μm, 100 Å, l/min.
The loading mobile (Phenomenex, Torrance, CA, USA) were: 0.1% TFA in
H2O (phase A) and 0.1% TFA in CH3CN (phase B). The elution mobile
phases compositions were: H2O 0.1% formic acid/CH3CN 97/3 (phase
A) and CH3CN 0.1% formic acid/H2O 97/3 (phase B). The elution program
was: 0 min, 4% B; 10 min, 40% B; 30 min, 65% B; 35 min, 65% B; 36 min,
90% B; 40 min, 90% B; 41 min, 4% B; and 60 min, 4% B. Mass spectra
were acquired in positive ion mode, setting the spray voltage at 2 kV,
the capillary voltage and temperature respectively at 45 V and 200 °C,
and the tube lens at 130 V. Data were acquired in data-dependent mode
with dynamic exclusion enabled (repeat count 2, repeat duration 15 s, ex-
clusion duration 30 s) surveyMS scans were recorded in the Orbitrap an-
alyzer in themass range 300–2000m/z at a 15,000 nominal resolution atFig. 5. Proteomic analysis of CAFs and DU145 after coculture and separation. CAFs were cult
Radioactively labeled CAFswere coculturedwithDU145, after 6 h the twopopulationswere sepa
proﬁle after colloidal Coomassie blue staining. (B–D) The images display the corresponding imm/z= 400; then up to three most intense ions in each full MS scan were
fragmented (isolation width 3 m/z, normalized collision energy 30) and
analyzed in the IT analyzer. Monocharged ions did not trigger MS/MS ex-
periments. The acquired data were searched with Mascot 2.4 search en-
gine (Matrix Science Ltd., London, UK) against the SwissProt database.
The taxonomywas restricted toH. sapiens. The experimental mass values
were monoisotopic. Searches were performed allowing: (i) up to one
missed cleavage sites, (ii) 10 ppm of tolerance for the monoisotopic pre-
cursor ion and 0.8 mass units for monoisotopic fragment ions, and (iii)
carbamidomethylation of cysteine as ﬁxed modiﬁcation and oxidation
of methionine as variable modiﬁcation. The criteria used to accept identi-
ﬁcations included the extent of sequence coverage, number of matched
peptides and probabilistic score sorted by the software.
2.17. Densitometric analysis of 2D gels
Scanned colloidal Coomassie blue images and autoradiographic im-
ages relative to gels containing 14C-proteins were analyzed by the
ImageMaster 2D Platinum software (GE Healthcare, USA). Only the
identiﬁed protein spots, corresponding to 14C-proteins present in all
the replicates of both ﬁbroblasts and DU145 gels, were taken intoured for 72 h in a complete medium supplemented with a mixture of 14C-amino acids.
rated and subjected to 2DE. (A–C) The images show the representative gels of their protein
ages obtained from the autoradiographies of the same gels.
Table 2


















1 P10599 Thioredoxin 4.76/13.25 4.82/12.01 3.0 21 83 695
2 P09382 Galectin-1 5.21/13.68 5.34/15.05 4.7 6 64 113
3 Q9UC61 Peptidyl-prolyl cis-trans isomerase A 7.70/17.90 7.68/18.23 2.9 9 62 128
4 Q9UC61 Peptidyl-prolyl cis-trans isomerase A 7.88/17.79 7.68/18.23 2.9 172 86 4150
5 P23528 Coﬁlin-1 8.01/19.92 8.22/18.72 3.3 11 65 152
6 P06753 Tropomyosin alpha-3 4.66/33.25 4.68/32.86 2.9 58⁎ 51⁎ 1413⁎
Q9UCS3 Tropomyosin alpha-4 4.67/28.62 44⁎ 53⁎ 1231⁎
7 Q9P2Z3 Superoxide dismutase (mitochondrial) 7.54/24.04 8.35/24.88 3.2 8 50 123
8 P60174 Triosephosphate isomerase 7.37/27.99 5.65/31.06 2.4 10 45 120
9 P18669 Phosphoglycerate mutase 1 7.33/29.43 6.67/28.90 1.8 124 83 3489
10 P04406 Glyceraldehyde-3-phosphate dehydrogenase 7.60/33.86 8.57/36.20 1.7 9 38 109
11 P04406 Glyceraldehyde-3-phosphate dehydrogenase 8.57/35.77 8.57/36.20 2.3 7 38 97
12 P04406 Glyceraldehyde-3-phosphate dehydrogenase 8.63/36.03 8.57/36.20 5.7 148 86 5004
P40926 Malate dehydrogenase, mitochondrial 8.92/35.94 39 59 1702
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 8.97/37.46 21 40 796
13 P04406 Glyceraldehyde-3-phosphate dehydrogenase 8.69/35.75 8.57/36.20 4.1 11 44 107 184
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 8.97/37.46 9 36 92
14 P40925 Malate dehydrogenase, cytoplasmic 7.34/36.90 6.91/36.63 1.6 7 27 83
15 P07355 Annexin A2 7.73/36.57 7.57/38.81 0.9 17 50 210
16 Q8N850 Vimentin 4.67/45.90 5.06/53.68 5.7 20 48 251
17 Q8N850 Vimentin 4.90/46.99 5.06/53.68 6.8 22 51 239
18 Q8N850 Vimentin 5.07/48.42 5.06/53.68 3.5 48 59 1433
19 Q8N850 Vimentin 5.10/50.48 5.06/53.68 3.6 82 78 2635
20 P06576 ATP synthase subunit beta, mitochondrial 5.21/51.42 5.26/56.52 7.6 19 74 238
P68363 Tubulin beta chain 4.94/50.80 15 43 70
21 Q8N850 Vimentin 5.36/52.34 5.06/53.68 11.3 47 85 399 427
22 Q6GMP2 Alpha-enolase 7.43/46.13 7.01/47.48 12.0 18 48 177
23 P14618 Pyruvate kinase M2 7.82/53.38 7.96/58.47 5.1 18 38 220
24 P27797 Calreticulin 4.20/58.10 4.29/48.28 1.0 8 25 120
⁎ 2 missed cleavages.
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tainingmultiple proteinswere excluded from the analysis. For each pro-
tein spot we determined the relative spot volume (V) with respect to
the total volume of the selected spots. The normalized %V of each spot
on replicate 2D gels was averaged and the mean values obtained for
the “stained spot” and for the “14C spot”were used to calculate the spe-
ciﬁc relative radioactivity of each spot, both in DU145 and in CAFs gels
(%V “14C-protein spot”/%V “stained spot”).
Transmission electron microscopy (TEM) three μl aliquots of both
ectosomes and exosomes suspensions were loaded onto a formvar/Table 3
Relative content of 14C-proteins transferred from CAFs to DU145.
Spot
N°
Protein name Speciﬁc radioactivit
% V (14C-Prot)/% V (
1 Thioredoxin 0.98 ± 0.28
2 Galectin-1 3.33 ± 0.09
3 Peptidyl-prolyl cis-trans isomerase A 0.97 ± 0.21
4 Peptidyl-prolyl cis-trans isomerase A 0.91 ± 0.11
6 Tropomyosin alpha 0.88 ± 0.19
7 Superoxide dismutase (mitochondrial) 3.59 ± 0.15
8 Triosephosphate isomerase 0.74 ± 0.23
9 Phosphoglycerate mutase 1 0.61 ± 0.01
10 Glyceraldehyde-3-P dehydrogenase 0.66 ± 0.02
14 Malate dehydrogenase (cytoplasmic) 1.52 ± 0.14
16 Vimentin 1.63 ± 0.16
7 Vimentin 1.80 ± 0.01
18 Vimentin 2.27 ± 0.23
19 Vimentin 1.17 ± 0.29
22 Alpha-enolase 0.61 ± 0.04
23 Pyruvate kinase M2 0.79 ± 0.01
24 Calreticulin 0.51 ± 0.04
The speciﬁc radioactivity was calculated as the ratio between the average normalized volume
obtained for each spot in colloidal Coomassie blue images. In turn, the speciﬁc enrichment o
calculated in the two cell populations. Bold: enriched proteins compared to their contents in Ccarbon-coated 400 mesh copper grid (Agar Scientiﬁc, Stansted, UK)
and negatively stained with 2.0% (w/v) uranyl acetate (Sigma). The
grid was air-dried and electron micrographs were acquired using a
JEM 1010 transmission electron microscope at 80 kV excitation voltage.
2.18. Statistical analysis
Data were expressed as mean ± SD. For comparison between
two groups, statistical signiﬁcance was determined by Student's test.
p values lower than 0.1 were considered signiﬁcant.y (DU145)
Prot)
Speciﬁc radioactivity (CAFs)
% V (14C-Prot)/% V (Prot)
Speciﬁc enrichment
(DU145/CAFs)
0.40 ± 0.10 2.47 ± 0.93
1.30 ± 0.12 2.56 ± 0.25
0.85 ± 0.16 1.14 ± 0.33
0.60 ± 0.14 1.51 ± 0.40
0.75 ± 0.08 1.18 ± 0.29
0.60 ± 0.11 5.97 ± 1.14
0.60 ± 0.04 1.24 ± 0.40
0.77 ± 0.34 0.79 ± 0.35
0.64 ± 0.07 1.04 ± 0.12
0.16 ± 0.04 9.28 ± 2.32
1.38 ± 0.14 1.18 ± 0.16
2.14 ± 0.18 0.84 ± 0.07
1.22 ± 0.10 1.85 ± 0.24
1.47 ± 0.57 0.79 ± 0.37
0.68 ± 0.06 0.90 ± 0.10
0.18 ± 0.01 4.48 ± 0.12
0.43 ± 0.02 1.18 ± 0.11
s obtained for each spot in autoradiography images and the average normalized volumes
f each protein was obtained from the ratio between the values of speciﬁc radioactivity
AFs.
Fig. 6. Size andmarkers characterization of CAFs released vesicles. (A–B) The vesicles secreted by CAFs were isolated and their size distributions were obtained using Dynamic Light Scat-
tering device. The average hydrodynamic diameter of vesicles within 10,000 ×g pellet (green) is 953.3 ± 168.8 nm. The average hydrodynamic diameter of vesicles within 100,000 ×g
pellet (purple) is 23.75 ± 4.252 nm. On the right the corresponding electron microscope images. (C)Western blot analysis performed on vesicles released by CAFs lysed in Laemmli elec-
trophoresis buffer.Whole cell lysate (WCL)was analyzed as control. Protein assaywas used to perform the equal loadingof vesicles samples. Themembranewas treatedwith anti-integrin
β1, anti-MMP2, and anti-CD81 antibodies. To asses the absence of contaminants due to cell death or apoptotic bodies, immuno-blotting was performed also for GM130, a Golgi apparatus
marker that is considered to be absent in EVs [26].
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Fig. 7.Western blot analysis of the two vesicles subpopulations secreted by CAFs. The ves-
icles released by CAFs were puriﬁed has described inMaterials andmethods section, lysed
in Laemmli electrophoresis buffer and the samples were used for SDS-PAGE followed by
Western blot analysis. Whole cell lysate (WCL) was analyzed as control. Protein assay
was used to perform the equal loading of each samples. The membranes were treated
with anti-enolase, anti-β-tubulin, anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), anti-piruvate kinase M1 (PKM1), anti-piruvate kinase M2 (PKM2), anti-
vimentin, anti-superoxide dismutase 2 (SOD2) and anti-GM130 antibodies. The GM130
absence in ectosomes and exosomes samples, conﬁrm they are free from cell debris or
other contaminants.
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3.1. Fibroblasts transfer proteins and lipids to surrounding cells
Primary human ﬁbroblasts are quickly converted to their activated
form (CAFs) when cultured with tumor cells, while CAFs, in turns,
have been shown to induce a marked increase (about 30–40%) in pros-
tate cancer cell proliferation [15,22]. Coculture experiments indicated
that CFDA-SE labeled proteins (Fig. 1A) and CellVue® labeled lipids
(Fig. 1B) are transferred from CAFs to DU145 cells in a time dependent
manner. When labeled DU145 cells were plated with unlabeled CAFs,
no transfer of either proteins (Fig. 1C) or lipids (Fig. 1D) was detected.
Proteins and lipids transfer between CAFs and cancer cells was quanti-
ﬁed by cytoﬂuorimetric assay in which we measured the ﬂuorescence
intensity increase of recipient cells after being cocultured for 24 h
with labeled donor cells (see Materials and methods). CAFs of prostatic
or dermal origin were able to transfer a high quantity of proteins and
lipids to tumor cells, while molecule transfer from tumor cells to ﬁbro-
blasts was remarkably lower or even absent (Fig. 2A, C). Primary ﬁbro-
blasts were found to transfer proteins to other non-transformed
recipient cells (Fig. 2B), indicating that this ability of ﬁbroblasts is a con-
stitutive property of this cell type. Exposure of ﬁbroblasts to tumor cell-
conditioned media, markedly increased this transfer process (Fig. 3)
with quantitative changes according to the type of tumor cells used.
The amount of transferred proteins was also found to depend on the
ratio between donor and recipient cells in coculture (Fig. 4A–B). More-
over, the overall mass of proteins transferred to tumor cells from
ﬁbroblasts correlated with an increase in proliferation of DU145 and
PC3 cells (Fig. 4C–D).
We next evaluated the time course of the protein transfer process by
labeling donor ﬁbroblasts with 14C-amino acids. After 24 h of cancer
cells/ﬁbroblast coculture, each ﬁbroblast has transferred about 4.0% of
its total protein mass to one DU145 cell and about 9.5% to one PC3 cell
(Table 1), conﬁrming that CAFs derived by PC3 cells conditioning are
able to transfer a greater amount of proteins respect to those derived
by DU145 conditioning (Fig. 3A).
3.2. Characterization of proteins transferred from CAFs to DU145
The approach we have implemented for the comprehensive proﬁl-
ing and identiﬁcation of proteins transferred from CAFs to cancer cells
involves the preliminary incorporation of 14C-amino acids into ﬁbro-
blasts proteins followed by 6 h of coculture with DU145 cells and sepa-
ration. Fig. 5 shows the representative gels of the protein proﬁles of
CAFs and DU145 cells obtained after colloidal Coomassie blue staining,
and the corresponding images obtained from autoradiography of the
dried gels. Identiﬁcation of main 14C-proteins transferred from CAFs to
DU145 is shown in Table 2. Densitometric analysis of the identiﬁed
radiolabeled proteins transferred to acceptor cells (Fig. 5D) revealed
that about 37% of them are structural proteins (vimentin and tropomy-
osin α) and about 34% are glycolytic enzymes. The remaining proteins
are a heterogeneous group of which the major components are ATP
synthase subunit β (7%), galectin-1 (4.7%), superoxide dismutase 2
(3%), and thioredoxin (3%).
We next evaluated the speciﬁcity of protein transfer (Table 3).While
structural proteins and glycolytic enzymeswere not enriched (ratio ~1)
in recipient cells (with the notable exception of PKM2), several other
proteins (thioredoxin, galectin-1, SOD2, malate dehydrogenase) were
speciﬁcally enriched in recipient cells with respect to donor cells
(ratio N1), suggesting that the protein transfer process from CAFs to
DU145 has some degree of speciﬁcity.
3.3. Role of extracellular vesicles in CAFs to tumor cells protein transfer
We characterized the extracellular vesicles released by CAFs, and in-
vestigated their possible involvement in the process of protein transferto tumor cells. Conditionedmedium from CAFs was processed to obtain
vesicles, and their size was determined by Dynamic Light Scattering
analysis. The 10,000 ×g pellet contained only one population of vesicles
with a diameter of about 1 μm, while the prevalent population of
vesicles within the 100,000 ×g pellet had a diameter of about 20 nm
(Fig. 6A–B). On the basis of marker expression [6] and their size, these
two populations can be classiﬁed as ectosomes and exosomes, respec-
tively (Fig. 6C). The absence of GM130 (a Golgi apparatus marker
which is absent in EVs) rules out that cell debris contribute to either
of these fractions [26]. Western blot analysis on both vesicle fractions
revealed that the most representative proteins transferred to tumor
cells (Table 2), are almost exclusively present in ectosomes (Fig. 7),
suggesting that they behave as cargo vesicles mediating the transfer of
proteins from CAFs to tumor cells.3.4. Effect of CAFs EVs delivery to cancer cell growth
To determine the relative importance of CAFs-derived EVs delivery
in cancer cell proliferation, we seeded DU145 and CAFs in 0.4 and
8.0 μm transwell dishes and measured DU145 proliferation and the rel-
ative amount of transferred proteins fromCAFs to DU145 in comparison
to classic CAFs-DU145 cocultures (Fig. 8). When CAFs and DU145 cells
were plated on 0.4 μm transwell, which is permeable to soluble factors
Fig. 8. CAFs proteinsﬂux toward cancer cells correlateswith tumor cells proliferation increase. (A) DU145were labeledwith CFDA-SE and then plated in single culture andwith ﬁbroblasts
in 1:2 ratio both in transwell system (membrane pore size of 0.4 μmand 8.0 μm) and in direct contact (coculture). After 40 h cells were detached and analyzed by ﬂow cytometry. The data
show the fold increase of proliferation index calculated on an average of three independent experiments (**p b 0.05; ***p b 0.01). (B) CAFs were labeled with CFDA-SE and then plated as
described above. After 24 h cells were detached and analyzed by ﬂow cytometry. The data represent the fold increase of DU145 recipient cells ﬂuorescence intensity, respect to their au-
toﬂuorescence intensity, calculated on an average of four independent experiments (***p b 0.01). (C) Measurement of 14C-lactate incorporation into DU145 proteins. CAFs and DU145
were plated as described above and treated for 24 h with 14C-lactate. DU145 proteins were puriﬁed (see Materials and methods) and the incorporated radioactivity was measured
(*p b 0.1; **p b 0.05; ***p b 0.01).
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served, although the overall quantity of proteins contained in CAFs-
derived exosomes was twice as much as the one due to ectosomes
(data not shown). In these conditions we observed only a limited
increase (6%) in DU145 cell proliferation compared to DU145 alone
(Fig. 8A), as the consequence of the action of soluble mediators. When
CAFs and DU145 cells were plated on 8.0 μm transwell dishes, which
allows the passage of all EVs, we observed protein transfer from CAFs
to DU145 (Fig. 8B) that is associated with a more relevant (16%)
increase in DU145 cell proliferation (Fig. 8A).
It has been previously shown that tumor cells coculturedwith ﬁbro-
blasts undergo a change in their metabolic properties, shifting from a
Warburg phenotype, essentially glycolytic, to a so-called reverse War-
burg phenotype [22], with a more respiratory phenotype sustained by
lactate released by ﬁbroblasts. Considering that several of the enzymes
transferred from ﬁbroblasts to DU145 cells belong to the glycolytic
pathway (Table 2) we tested whether proteins transferred to tumor
cells could be involved in this metabolic shift. The use of lactate for an-
abolic purpose was found to be much greater when tumor cells receive
ﬁbroblasts proteins (8.0 μm transwell and coculture conditions, Fig. 8C),
suggesting that proteins derived from ﬁbroblasts may contribute to the
metabolic shift of cancer cells toward a reverse Warburg phenotype,
more efﬁcient in highly proliferating conditions [27]. In addition, incu-
bating DU145 cells with ectosomes puriﬁed from CAFs we observed
an increase in DU145 proliferation while exosomes had a lower effect
(Fig. 9). These data conﬁrm that ectosomes-mediated protein and
lipid transfer from ﬁbroblasts is the main responsible for the increase
of DU145 cell proliferation in coculture.4. Discussion
Fibroblasts are the most abundant cellular elements in connective
tissue that constitutes the structural scaffold of organs. Fibroblasts syn-
thesizemany of the constituents of ECM (collagens I, II and V, and ﬁbro-
nectin) [28,29] and basal lamina (collagen IV and laminin), and are
responsible for the remodeling and turnover of ECMby secretingmatrix
metalloproteinases (MMPs) [30,31]. In addition,ﬁbroblasts regulate dif-
ferentiation and homeostasis of adjacent epithelia through the secretion
of growth factors and cytokines [32]. In some physiological (i.e., wound
healing and inﬂammation) or pathological (cancer) conditions, ﬁbro-
blasts assume an “activated” phenotype consequent to their stimulation
with growth factors or cytokines (TGF-β, EGF, b-FGF) [33,34]. In tumor
microenvironment CAFs actively contribute to tumor progression by:
i) enhancing tumor cell proliferation [15]; ii) favoring cancer cell mobil-
ity; iii) sustaining a stem-like phenotype in cancer cells; iv) shaping the
reactivity of other accessory stromal cells [35]; v) altering the structural
characteristics of tumor microenvironment, enhancing pericellular
acidity and secreting matrix proteins [16]; and vi) guiding cancer cells
in the bloodstream and sustaining their survival until they reach the
metastatic site [36].
In the present study we provide evidence that extensive transfer of
biomass, i.e. proteins and lipids, to cancer cells is an additional process,
mediated by normal human ﬁbroblasts and CAFs, that contributes to
enhance tumor cell proliferation [15,22]. Confocal microscopy experi-
ments on ﬁbroblasts/tumor cell coculture revealed that CAFs can
horizontally transfer their proteins and lipids in a time-dependentman-
ner to tumor cells, while the passage of material from tumor cells to
Fig. 9. Effect of CAFs derived exosomes or ectosomes on tumor cells growth. DU145 were
labeled with CFDA-SE and then plated in starvation medium alone or supplemented with
exosomes or ectosomes puriﬁed from CAFs. After 40 h cells were detached and analyzed
by ﬂow cytometry. The data show the fold increase of proliferation index calculated on
an average of four independent experiments (*****p b 0.001).
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between various types of tumor cells lines and human ﬁbroblasts of
different origins revealed that: i) prostatic or dermal ﬁbroblasts are
able to transfer proteins and lipids to every type of cancer cells
examined; ii) the capability of tumor cells to transfer proteins is negligi-
ble; and iii) protein transfer capacity is an intrinsic property of
non-activated ﬁbroblasts since we observed this phenomenon in all
types of ﬁbroblasts. Nonetheless, ﬁbroblasts activated with tumor
cell-conditionedmediamarkedly enhance their protein transfer activity
and, interestingly, the extent of this phenomenon is dependent on the
type of tumor cells (Fig. 3).
The ability of CAFs to enhance tumor cell growth was found to be
quantitatively linked to the overall quantity of transferred proteins to
cancer cells. In agreement with this observation, protein transfer from
CAFs was characterized by a high ﬂux, as in 24 h 4.0% to 9.0% of total
protein mass of CAFs was transferred to DU145 and PC3, respectively.
Considering that ﬁbroblasts have a higher mass with respect to that of
cancer cells, proteins received by cancer cells in every generation repre-
sent a signiﬁcant fraction of their own overall protein content. We have
also identiﬁed the major proteins which are transferred to tumor cells,
and found that structural proteins (vimentin and tropomyosin α) and
glycolytic enzymes (enolase, GADPH, PKM2, etc) represent about 70%
of the total transferred mass, but, with the exception of PKM2, they
are not enriched in recipient cells with respect to donor ones. On the
contrary, several other CAFs proteins (thioredoxin, galectin-1, SOD2,Fig. 10. Ectosomes from CAFs sustain cancer cell proliferation. Cancer cells-derived soluble fact
CAFs results in a marked increase of their protein transfer ﬂux toward tumor cells mediated by
sustain their high proliferation rate.malate dehydrogenase) are speciﬁcally transferred to tumor cells,
although the physiologic relevance of this phenomenon is currently
unknown.
Protein transfer was found to be essentially mediated by ﬁbroblast-
released ectosomes, which represent a form of intercellular communi-
cation that is far less studied with respect to exosomes. Data from the
present study indicate that ectosomes produced by CAFs are the most
important mechanism by which the ﬁbroblast component of tumor
microenvironment enhances cancer cell growth. In fact, using ﬁlters
which do not allow transfer of ectosomes, the proliferation rate of
DU145 cells was only slightly higher compared to that of DU145
alone, and no signiﬁcant protein transfer from CAFs to DU145 was
observed. In this condition, the effect on DU145 is likely mediated by
soluble factors release and by the passage of exosomes. When DU145
and CAFs were separated by a 8.0 μm ﬁlters, which are freely permeable
to ectosomes, we observed a considerable passage of CAFs proteins to
DU145. More important, this phenomenon was associated with a clear
increase in DU145 proliferation rate (Fig. 8A). In classical coculture
conditions, where ectosome-mediated protein transfer is maximized,
a maximal induction of DU145 proliferation was observed.
In conclusion ectosomes-mediated protein and lipid transfer from
CAFs to tumor cells is the most important phenomenon that explains
the cancer cell proliferation boost in our tumor microenvironment
model (Fig. 10). This is a quantitative phenomenon due to the transfer
of a speciﬁc subset of proteins, as the tumor cells phenotypic outcome
correlates with the amount of protein transfer. The relative contribute
of each single protein, if any, is yet to be determined, however here
we show that the shift of cancer cells to reverse Warburg metabolism
[37], a kind of metabolic asset more favorable for cell proliferation
[22,27], could be favored by the CAFs to cancer cells transfer of enzymes
of the second part of glycolysis.
In summary, our data reveal a general function of ﬁbroblasts related
to the intrinsic trophic activity of connective tissue, that consists in a
supporting action on neighboring cells bymeans of constitutive produc-
tion of ectosomes. In the context of tumor microenvironment, the
conversion of normal ﬁbroblasts into CAFs leads to a signiﬁcant
enhancement of their protein transfer ﬂux toward tumor cells contrib-
uting to sustain the high proliferation rate of tumor tissue.
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